For its fourth fiscal quarter (ending December 31), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has reported a 111% increase in E.P.S. from $1.50 a year ago to $3.16 in the current quarter. E.P.S. were $9.06 for the latest four quarters through December 31 versus $6.55 for the same period a year ago — an increase of 38%.
Recent Price Action
On 2/25/25, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock enjoyed a large increase of 2.2%, closing at $139.67. Moreover, this advance was accompanied by unusually high trading volume at 196% of normal. Relative to the market the stock has been strong over the last nine months and has risen 4.3% during the last week.
Current PriceTarget Research Rating
Jazz Pharmaceuticals plc has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. Jazz Pharmaceuticals plc has a slightly positive Power Rating of 68 and a very high Appreciation Score of 86, resulting in the Highest Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment